Package Leaflet: Information for the Patient
Venclyxto 10mg film-coated tablets
Venclyxto 50mg film-coated tablets
Venclyxto 100mg film-coated tablets
venetoclax
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
What is Venclyxto
Venclyxto is a cancer medicine that contains the active substance venetoclax. It belongs to a group of medicines called “BCL-2 inhibitors”.
What is Venclyxto used for
Venclyxto is used to treat adults with:
CLL is a type of cancer that affects a type of white blood cell called lymphocytes and lymph nodes. In CLL, lymphocytes multiply too quickly and live too long, so there are too many of them in the blood.
AML is a type of cancer that affects a type of white blood cell called myeloid cells. In AML, myeloid cells multiply and grow very quickly in the bone marrow and in the blood, so there are too many of them and not enough red blood cells in the blood.
How Venclyxto works
Venclyxto works by blocking a protein in the body called “BCL-2”. This protein is found in high amounts in some cancer cells and helps cancer cells to survive. Blocking this protein helps to destroy cancer cells and reduce their number. It also delays the worsening of the disease.
Do not take Venclyxto if:
Once the dose of Venclyxto has been increased to the full standard dose, ask your doctor if you can start taking these medicines again.
It is important that you tell your doctor, pharmacist or nurse about all the medicines you are taking, including those bought without a prescription, vitamins and herbal supplements. Your doctor may ask you to stop taking certain medicines when you start taking Venclyxto and during the first few days or weeks, during the increase in dose to the full standard dose.
Warnings and precautions
Talk to your doctor, pharmacist or nurse before you start taking Venclyxto if:
If you are in any of these situations, or are not sure, talk to your doctor, pharmacist or nurse before taking this medicine.
Tumour Lysis Syndrome
Some people may have high levels of certain salts in the blood (such as potassium and uric acid) due to the rapid breakdown of cancer cells during treatment. This can cause problems with kidney function, an abnormal heart rhythm or seizures. This condition is called tumour lysis syndrome (TLS). The risk of TLS is highest in the first few days or weeks of treatment with Venclyxto, when the dose is being increased.
If you have CLL
Your doctor, pharmacist or nurse will do blood tests to check for TLS.
Before you start treatment with Venclyxto, your doctor will give you medicines to help prevent the build-up of uric acid in your body.
Drinking plenty of water, at least 1.5 to 2 litres a day, helps to remove waste products from cancer cells from the body through the urine and may reduce the risk of TLS (see section 3).
Tell your doctor, pharmacist or nurse immediately if you have any of the symptoms of TLS listed in section 4.
If you are at risk of TLS, you may receive treatment in hospital so that you can be given extra fluids through a vein if needed, have more frequent blood tests and be checked for side effects. This is to make sure it is safe for you to continue taking this medicine.
If you have AML
You may receive treatment in hospital and your doctor or nurse will make sure you have enough water or fluids, give you medicines to prevent the build-up of uric acid in your body and do blood tests before you start taking Venclyxto, while the dose is being increased and when you start taking the full dose.
Children and adolescents
Venclyxto must not be used in children and adolescents.
Other medicines and Venclyxto
Tell your doctor or pharmacist if you are taking any of the following medicines, as they may increase or decrease the amount of venetoclax in the blood:
Your doctor may need to change your dose of Venclyxto.
Tell your doctor if you are taking any of the following medicines, as Venclyxto may affect how they work:
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including those bought without a prescription, herbal medicines and supplements. This is because Venclyxto may affect how they work and they may affect how Venclyxto works.
Taking Venclyxto with food and drink
Do not take products containing grapefruit, Seville oranges (bitter oranges, often used in marmalades) or starfruit while you are taking Venclyxto - do not eat them, drink their juice or take supplements that may contain them. This is because they can increase the amount of venetoclax in the blood.
Pregnancy
Contraception
Breast-feeding
Do not breast-feed while you are taking this medicine. It is not known whether the active substance in Venclyxto passes into breast milk.
Fertility
Based on the results of animal studies, Venclyxto may cause male infertility (reduced or absent sperm count). This may affect your ability to father a child. Ask your doctor about storing sperm before you start treatment with Venclyxto.
Driving and using machines
After taking Venclyxto, you may feel tired or dizzy, which may affect your ability to drive and use tools or machines. If this happens, do not drive or use any tools or machines.
Venclyxto contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose, which is essentially “sodium-free”.
Follow exactly the instructions of your doctor, pharmacist or nurse for taking this medicine. If you are not sure, talk to your doctor, pharmacist or nurse again.
How much to take
If you have CLL
You will start treatment with Venclyxto at a low dose for 1 week. Your doctor will gradually increase the dose over the next 4 weeks to the full standard dose. During the first 4 weeks, you will receive a new pack each week.
A dose adjustment may be necessary due to side effects. Your doctor will tell you what dose to take.
If you have AML
You will start treatment with Venclyxto at a lower dose. Your doctor will gradually increase the dose each day over the first 3 days. After 3 days, you will take the full standard dose. The dose (tablets) is taken once a day.
The following table shows the doses
Day | Daily dose of Venclyxto |
1 | 100 mg (1 x 100 mg tablet) |
2 | 200 mg (2 x 100 mg tablets) |
3 and after | 400 mg (4 x 100 mg tablets) |
Your doctor will give you Venclyxto in combination with another medicine (azacitidine or decitabine).
You will continue to take the full dose of Venclyxto until your AML gets worse or you can no longer take Venclyxto because it is causing serious side effects.
How to take Venclyxto
If you vomit after taking Venclyxto, do not take an extra dose that day. Take your next dose at the usual time the next day. If you have problems taking this medicine, talk to your doctor.
Drink plenty of water
If you have CLL
It is very important that you drink plenty of water while you are taking Venclyxto during the first 5 weeks of treatment. This will help to remove waste products from cancer cells from the body through the urine.
You should start drinking at least 1.5 to 2 litres of water a day, 2 days before you start Venclyxto. You can also include non-caffeinated and non-alcoholic drinks in this amount, but do not drink grapefruit, Seville orange or starfruit juice. You should continue to drink at least 1.5 to 2 litres of water on the day you start Venclyxto. Drink the same amount of water (at least 1.5 to 2 litres a day) 2 days before your dose is increased and on the day of the increase.
If your doctor thinks you are at risk of TLS, you may receive treatment in hospital so that you can be given extra fluids through a vein if needed, have more frequent blood tests and be checked for side effects. This is to make sure it is safe for you to continue taking this medicine.
If you have AML
It is very important that you drink plenty of water while you are taking Venclyxto, especially when you start treatment and when the dose is increased. Drinking water will help to remove waste products from cancer cells from the body through the urine. If you are in hospital, your doctor or nurse will give you fluids through a vein if needed to make sure this happens.
If you take more Venclyxto than you should
If you take more Venclyxto than you should, talk to a doctor, pharmacist or nurse or go to hospital immediately. Take the tablets and this leaflet with you.
If you forget to take Venclyxto
If you stop taking Venclyxto
Do not stop taking this medicine unless your doctor tells you to. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. This medicine may cause the following serious adverse effects:
Tumor Lysis Syndrome(frequent - may affect up to 1 in 10 people)
Stop taking Venclyxto and seek immediate medical attention if you notice any of the symptoms of TLS:
Decrease in White Blood Cell Count (Neutropenia) and Infections(very frequent - may affect more than 1 in 10 people)
Your doctor will check your blood cell count during treatment with Venclyxto. A decrease in white blood cells can increase the risk of infections. The signs may be fever, chills, weakness, or confusion, cough, pain or burning sensation when urinating. Some infections, such as pneumonia or blood infection (sepsis), can be severe and life-threatening. Inform your doctor immediately if you have signs of infection during treatment with this medicine.
Inform your doctor if you notice any of the following adverse effects:
If you have CLL
Very Frequent(may affect more than 1 in 10 people)
Also, the following may be observed in blood tests:
Frequent(may affect up to 1 in 10 people)
Also, the following may be observed in blood tests:
If you have LMA
Very Frequent(may affect more than 1 in 10 people)
Blood tests may show:
Frequent(may affect up to 1 in 10 people)
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the blister label and carton, after EXP.:
No special storage conditions are required.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Venclyxto Composition
The active substance is venetoclax.
The other ingredients are:
In the film coating:
Appearance of the Product and Package Contents
Venclyxto 10 mg film-coated tablet is pale yellow, round, 6 mm in diameter, marked with a V on one side and 10 on the other.
Venclyxto 50 mg film-coated tablet is beige, oblong, 14 mm long, marked with a V on one side and 50 on the other.
Venclyxto 100 mg film-coated tablet is pale yellow, oblong, 17.2 mm long, marked with a V on one side and 100 on the other.
Venclyxto tablets are available in blisters or bottles contained in cartons as follows:
Venclyxto 10 mg film-coated tablets:
Venclyxto 50 mg film-coated tablets:
Venclyxto 100 mg film-coated tablets:
Not all pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
AbbVie Deutschland GmbH & Co. KG
Knollstrasse
67061 Ludwigshafen
Germany
AbbVie S.r.l.
S.R. 148 Pontina, km 52 SNC
04011 Campoverde di Aprilia (Latina)
Italy
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien AbbVie SA Tel: +32 10 477811 | Lietuva AbbVie UAB Tel: +370 5 205 3023 |
Luxembourg/Luxemburg AbbVie SA Belgique/Belgien Tel: +32 10 477811 | |
Ceská republika AbbVie s.r.o. Tel: +420 233 098 111 | Magyarország AbbVie Kft. Tel: +36 1 455 8600 |
Danmark AbbVie A/S Tlf: +45 72 30-20-28 | Malta V.J.Salomone Pharma Limited Tel: +356 22983201 |
Deutschland AbbVie Deutschland GmbH & Co. KG Tel: 00800 222843 33 (free of charge) Tel: +49 (0) 611 / 1720-0 | Nederland AbbVie B.V. Tel: +31 (0)88 322 2843 |
Eesti AbbVie OÜ Tel: +372 623 1011 | Norge AbbVie AS Tlf: +47 67 81 80 00 |
Ελλάδα AbbVie ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε. Τηλ: +30 214 4165 555 | Österreich AbbVie GmbH Tel: +43 1 20589-0 |
España AbbVie Spain, S.L.U. Tel: +34 91 384 09 10 | Polska AbbVie Sp. z o.o. Tel.: +48 22 372 78 00 |
France AbbVie Tél: +33 (0) 1 45 60 13 00 | Portugal AbbVie, Lda. Tel: +351 (0)21 1908400 |
Hrvatska AbbVie d.o.o. Tel: + 385 (0)1 5625 501 | România AbbVie S.R.L. Tel: +40 21 529 30 35 |
Ireland AbbVie Limited Tel: +353 (0)1 4287900 | Slovenija AbbVie Biofarmacevtska družba d.o.o. Tel: +386 (1)32 08 060 |
Ísland Vistor hf. Tel: +354 535 7000 | Slovenská republika AbbVie s.r.o. Tel: +421 2 5050 0777 |
Italia AbbVie S.r.l. Tel: +39 06 928921 | Suomi/Finland AbbVie Oy Puh/Tel: +358 (0)10 2411 200 |
Κύπρος Lifepharma (Z.A.M.) Ltd Τηλ: +357 22 34 74 40 | Sverige AbbVie AB Tel: +46 (0)8 684 44 600 |
Latvija AbbVie SIA Tel: +371 67605000 |
Date of Last Revision of this Leaflet:
Other Sources of Information
Detailed information about this medicine is available on the European Medicines Agency website http://www.ema.europa.eu.
The leaflet can be found in all languages of the European Union/European Economic Area on the European Medicines Agency website.
To listen to this leaflet or request a copy in Braille, large print, or audio, contact the local representative of the marketing authorization holder.